v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flow from operating activities:    
Net loss $ (10,611,000) $ (13,859,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Debt issuance costs 319,000  
Change in fair value of loan facility (198,000) 760,000
Change in fair value of warrant liabilities 625,000 (378,000)
Depreciation and amortization 627,000 521,000
Stock-based compensation 1,101,000 2,694,000
Non-cash lease expense 233,000 215,000
Loss on fixed asset disposal 53,000 14,000
Loss on patent disposal 2,000  
Remeasurement and foreign currency transaction loss 9,000  
Excess and obsolete inventory related charges 57,000 313,000
Provision for credit losses 0 (7,000)
Amortization of premium of marketable securities (77,000) (128,000)
Non-cash changes in the fair value of NQDC plan 19,000 (695,000)
Changes in operating assets and liabilities:    
Trade and other receivables (799,000) (253,000)
Prepaids and other current assets (90,000) 350,000
Inventory 752,000 (1,439,000)
Operating lease liability (154,000) (231,000)
Corporate-owned life insurance ("COLI") asset 0 492,000
Other long-term assets 77,000 259,000
Accounts payable and accrued expenses (1,786,000) 2,330,000
Accrued wages and fringe benefits 57,000 (2,105,000)
Current non-qualified deferred compensation liability 262,000 (1,567,000)
Other current liabilities (481,000) 1,119,000
Non-qualified deferred compensation plan liability (61,000) 1,294,000
Contract liabilities (8,000) (8,000)
Net cash used in operating activities (10,072,000) (10,309,000)
Cash flow from investing activities:    
Purchase of marketable securities (3,937,000)  
Maturities of marketable securities 6,000,000 11,000,000
Purchase of plant and equipment (19,000) (221,000)
Patent filing fees (3,000) (13,000)
Net cash provided by investing activities 2,041,000 10,766,000
Cash flow from financing activities:    
Proceeds from loan facility, net of issuance costs 49,081,000  
Repayment of Previous Credit Agreement (42,984,000)  
Proceeds from exercise of stock options 0 363,000
Net cash provided by financing activities 6,097,000 363,000
Net increase/(decrease) in cash and cash equivalents (1,934,000) 820,000
Cash and cash equivalents beginning of the period 10,243,000 14,050,000
Cash and cash equivalents end of the period 8,309,000 14,870,000
Supplemental Disclosure of Cash Flow Information:    
Interest paid during the period 1,421,000 1,232,000
Non-cash investing activities:    
Capital expenditures not yet paid 55 $ 168
Non-cash financing activities:    
Exercise of penny warrants 718,000  
Warrant liability recognized upon issuance of loan facility $ 1,043,000